Outbreaks of Pneumocystis pneumonia have been described in renal transplant recipients. Aerosolized pentamidine is frequently used for prophylaxis in this setting. We report our experience with aerosolized pentamidine use in 56 renal transplant recipients. We found high rates of adverse reactions in patients with chronic respiratory disease. O utbreaks of Pneumocystis pneumonia (PCP) in renal transplant recipients have been reported (1-4). Due to the perceived toxicity of other therapies, aerosolized pentamidine (AP) is frequently used as a second-line agent for PCP prophylaxis, yet there are limited data on the safety and efficacy of AP in solidorgan transplantation (SOT). In 2010 to 2012, there was a PCP outbreak affecting renal transplant recipients in eastern Australia, with eight cases at our institution, where universal prophylaxis was introduced (5). We conducted a review to determine the safety and efficacy of AP use in a postoutbreak setting and to assess whether patients can be safely rechallenged with trimethoprimsulfamethoxazole (TMP-SMX) following AP use. We present the largest cohort of SOT recipients receiving AP to date.
were documented in 19 of 29 (66%) patients, with renal impairment, rash, and leukopenia being the most common (7/ AP-associated adverse reactions required AP discontinuation in 5 of 56 (9%) patients (Table 2) . Four patients had bronchospasm, and 1 patient required intensive care admission for epinephrine infusion. All 5 patients had a history of respiratory disease (5/5 versus 1/51; P Ͻ 0.0001, Fisher's exact test) but were not receiving regular respiratory medications at the time of reaction. Three patients were recommenced on TMP-SMX following their AP reactions, and 2 of these remained on TMP-SMX without complications. No patients developed PCP during the course of prophylaxis, including those receiving AP prophylaxis.
AP is often considered a useful alternative for PCP prophylaxis in SOT recipients given that it is administered monthly and has a perceived lack of adverse effects (6, 7); however, our data suggest that this presumed safety may not always be the case. Although bronchospasm is a recognized complication of AP use (6-8), our report is notable because all of the patients who experienced bronchospasm had a history of chronic respiratory disease. Based on this observation, clinicians should exercise particular caution when administering AP to patients with chronic respiratory dis-ease and perhaps even consider the presence of respiratory disease a potential contraindication to AP use. Although genetic variations in the ␤ 2 -adrenoreceptor gene may explain some of the variation in response to ␤ 2 -agonists (9), further studies are needed to establish their role in this potentially life-threatening adverse event.
Notably, 22 patients in our cohort underwent rechallenge with TMP-SMX, the majority (17/22) successfully. Unlike patients receiving AP, no patients receiving TMP-SMX required hospitalization. Thus, TMP-SMX remains the primary recommended treatment and prophylaxis regimen for PCP (10, 11) ; in addition, it has the concurrent effect of preventing toxoplasmosis and some Gram-negative infections (12) . Our findings suggest that, if carefully monitored, TMP-SMX prophylaxis can be safely and successfully used in many patients with renal impairment and hematological abnormalities without the need to switch to other regimens, such as AP. Although Mitsides et al. (13) reported similar findings in 290 renal transplant recipients receiving TMP-SMX following a PCP outbreak, they noted a high rate of TMP-SMX discontinuation, predominantly due to renal impairment.
Our study had some limitations. First, its retrospective nature makes comparison of the management of adverse events between patients difficult. Although we reported only our experience with AP use, it would be valuable to examine the overall experience of universal PCP prophylaxis following an outbreak, in order to better define whether a more targeted approach may be warranted and to compare the safety and efficacy of various prophylactic regimens. Second, while bronchospasm sufficient to cause significant hypoxia and require supplemental oxygen was a key complication of AP use in our cohort (Table 2) , we did not perform formal spirometry on our patients due to the acuity of their reactions. Episode of CMV viremia or disease 1 year prior to or during PCP prophylaxis In conclusion, although AP appeared to be an efficacious regimen for PCP prophylaxis in an outbreak setting, it was associated with potentially life-threatening adverse events, occurring predominantly in patients with chronic respiratory disease. TMP-SMX should therefore remain the first choice for PCP prophylaxis, and patients should be rechallenged if possible, especially given the superior efficacy of TMP-SMX (8), its lower cost (14) , and the potential benefit in prophylaxis for other opportunistic infections (12) . The role of universal prophylaxis in PCP outbreaks remains to be determined, and a more targeted approach that takes into account clinical characteristics such as the "net" state of immunosuppression (15) , biomarkers, and level of exposure may be warranted.
